|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol显示文摘 | Thomas Reiberger Gregor Ulbrich Arnulf Ferlitsch Berit Anna Payer Philipp Schwabl Matthias Pinter Birgit B Heinisch Michael Trauner Ludwig Kramer Markus Peck-Radosavljevic | 2013 | Gut2013，，11： | 2 |
| 2 | How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma显示文摘 | Florian Hucke Matthias Pinter Ivo Graziadei Simona Bota Wolfgang Vogel Christian Müller Harald Heinzl Fredrik Waneck Michael Trauner Markus Peck-Radosavljevic Wolfgang Sieghart | 2014 | Journal of Hepatology2014，，： | 2 |
| 3 | Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis显示文摘 | ] Matthias Pinter Wolfgang Sieghart Ivo Graziadei | 2009 | The Oncologist2009，14，1： | 1 |
| 4 | Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma显示文摘 | Wolfgang Sieghart Matthias Pinter Bernhard Dauser Natalya Rohr-Udilova Anne-Christine Piguet Gerald Prager Hubert Hayden Hans-Peter Dienes Jean-Francois Dufour Markus Peck-Radosavljevic | 2012 | Journal of Hepatology2012，，3： | 1 |
| 5 | Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol显示文摘 | Thomas Reiberger Gregor Ulbrich Arnulf Ferlitsch Berit Anna Payer Philipp Schwabl Matthias Pinter Birgit B Heinisch Michael Trauner Ludwig Kramer Markus Peck-Radosavljevic | 2013 | Gut2013，，11： | 1 |
| 6 | Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study显示文摘 | Wolfgang Sieghart Matthias Pinter Michael Reisegger Christian Müller Ahmed Ba-Ssalamah Johannes Lammer Markus Peck-Radosavljevic | 2012 | European Radiology2012，，6： | 1 |
| 7 | Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study显示文摘 | Wolfgang Sieghart Matthias Pinter Michael Reisegger Christian Müller Ahmed Ba-Ssalamah Johannes Lammer Markus Peck-Radosavljevic | 2012 | European Radiology2012，，6： | 1 |
| 8 | Leaf nitrogen concentration of wheat subjected to elevated and either water or N deficits 显示文摘 | Sinclair T R Pinter P J Kimball B A Adamsen F J LaMorte R L Wall G W Hunsaker D l Adam N Brooks T J Garcia R L Thompson T Leavitt S Matthias A | 2000 | Agriculture Ecosystem & Environment2000，79，1： | 1 |
| 9 | The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma显示文摘 | Wolfgang Sieghart Florian Hucke Matthias Pinter Ivo Graziadei Wolfgang Vogel Christian Müller Harald Heinzl Michael Trauner Markus Peck‐Radosavljevic | 2013 | Hepatology2013，，6： | 1 |
| 10 | Free-air CO 2 enrichment effects on the energy balance and evapotranspiration of sorghum显示文摘 | J.M Triggs B.A Kimball P.J Pinter G.W Wall M.M Conley T.J Brooks R.L LaMorte N.R Adam M.J Ottman A.D Matthias S.W Leavitt R.S Cerveny | 2004 | Agricultural and Forest Meteorology2004，，1： | 1 |
| 11 | Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma显示文摘BACKGROUND A well-recognized class effect of immune checkpoint inhibitors(ICI)is immune-related adverse events(IrAEs)ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation of ICI.Deaths are reported in<5%of patients treated with ICI.There are,however,no reliable markers to predict the onset and severity of IrAEs.We tested the association between neutrophil-lymphocyte ratio(NLR)and platelet-lymphocyte ratio(PLR)at baseline with development of clinically significant IrAEs(grade≥2)in hepatocellular carcinoma(HCC)patients treated with ICI.AIM To test the association between NLR and PLR at baseline with development of clinically significant IrAEs(grade≥2)in HCC patients treated with ICI.METHODS Data was extracted from an international database from a consortium of 11 tertiary-care referral centers.NLR=absolute neutrophil count/absolute lymphocyte count(ALC)and PLR=platelet count/ALC.Cutoff of 5 was used for NLR and 300 for PLR based on literature.We also tested the association between RESULTS Data was collected from 361 patients treated between 2016-2020 across the United States(67%),Asia(14%)and Europe(19%).Most patients received Nivolumab(n=255,71%).One hundred sixty-seven(46%)patients developed at least one IrAE,highest grade 1 in 80(48%),grade≥2 in 87(52%)patients.In a univariable regression model PLR>300 was significantly associated with a lower incidence of grade≥2 IrAEs(OR=0.40;P=0.044).Similarly,a trend was observed between NLR>5 and lower incidence of grade≥2 IrAEs(OR=0.58;P=0.097).Multivariate analyses confirmed PLR>300 as an independent predictive marker of grade≥2 IrAEs(OR=0.26;P=0.011),in addition to treatment with programmed cell death ligand 1(PD-1)/cytotoxic T lymphocyte-associated protein-4(OR=2.57;P=0.037)and PD-1/tyrosine kinase inhibitor(OR=3.39;P=0.01)combinations.Antibiotic use was not associated with IrAE incidence(OR=1.02;P=0.954).Patients treated with steroids had a>2-fold higher incidence of grade≥2 IrAEs(OR=2.74;P<0.001),although 74%were prescribed steroids for the treatment of IrAEs.CONCLUSION Given that high baseline NLR and PLR are associated with a decreased incidence of IrAEs,lower baseline NLR and PLR may be predictive biomarkers for the appearance of IrAEs in HCC treated with ICI.This finding is in keeping with several studies in solid tumors that have shown that baseline NLR and PLR appear predictive of IrAEs. | Sirish Dharmapuri UmutÖzbek Hiren Jethra Tomi Jun Thomas U Marron Anwaar Saeed Yi-Hsiang Huang Mahvish Muzaffar Matthias Pinter Lorenz Balcar Claudia Fulgenzi Suneetha Amara Arndt Weinmann Nicola Personeni Bernhard Scheiner Tiziana Pressiani Musharraf Navaid Bertram Bengsch Sonal Paul Uqba Khan Dominik Bettinger Naoshi Nishida Yehia Ibrahim Mohamed Arndt Vogel Anuhya Gampa James Korolewicz Antonella Cammarota Ahmed Kaseb Peter R Galle Anjana Pillai Ying-Hong Wan Alessio Cortellini Masatoshi Kudo Antonio D’Alessio Lorenza Rimassa David James Pinato Celina Ang | 2023 | World Journal of Gastrointestinal Oncology2023，15，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员